|Systematic (IUPAC) name|
|Licence data||US Daily Med:|
|Metabolism||hepatic (at least partly mediated by CYP2D6)|
|(what is this?)|
Thioridazine (Mellaril (DE, BD, ET, ID, BR), Melleril (withdrawn worldwide in 2005), Sonapax (RU), Thioril (IN)) is a piperidine typical antipsychotic drug belonging to the phenothiazine drug group and was previously widely used in the treatment of schizophrenia and psychosis. Due to concerns about cardiotoxicity and retinopathy at high doses this drug has been withdrawn in many countries (including the UK and Australia) and in other countries it is not commonly prescribed, reserved for patients who have failed to respond to, or have contraindications for, more widely used antipsychotics.
In older references, it is sometimes described as atypical, but more recently it is usually described as typical, with the term "atypical" usually reserved for agents showing D4 selectivity or serotonin antagonism. The atypicality of second generation agents is not clearly defined. Some believe it's low D2 affinity, quick dissociation, 5-HT2A receptor antagonism, or all of the above. Its perceived atypical effects (namely its comparatively low propensity for extrapyramidal side effects) are likely the result of its potent anticholinergic effects.
Thioridazine is known to kill intracellular extensively drug-resistant (XDR) Mycobacterium tuberculosis and both inhibit MRSA directly but also increase the susceptibility of MRSA to β-lactam antibiotics at clinical concentrations. It also appears to increase the efficacy of standard antimicrobial agents (even ones to which the strain in question is resistant) in treating XDR-tuberculosis (XDR-TB) via inhibiting bacterial efflux pumps.
The product Melleril® has been voluntarily discontinued by its manufacturer, Novartis, worldwide. Consequently it was withdrawn from the UK and Canada in July 2005. Stocks of Melleril ran out in Australia in August 2007.
For further information see: Phenothiazine
Thioridazine prolongs the QTc interval in a dose-dependent manner. It produces significantly less extrapyramidal side effects than most first-generation antipsychotics. Its use, along with the use of other typical antipsychotics, has been associated with degenerative retinopathies. It has a higher propensity for causing anticholinergic side effects coupled with a lower propensity for causing extrapyramidal side effects and sedation than chlorpromazine, but also has a higher incidence of hypotension and cardiotoxicity. It is also known to possess a relatively high liability for causing orthostatic hypotension compared to other antipsychotics. Similarly to other first-generation antipsychotics it has a relatively high liability for causing prolactin elevation. It is moderate risk for causing weight gain. As with all antipsychotics thioridazine has been linked to cases of tardive dyskinesia (an often permanent neurological disorder characterised by slow, repetitive, purposeless and involuntary movements, most often of the facial muscles, that is usually brought on by years of continued treatment with antipsychotics, especially the first-generation (or typical) antipsychotics such as thioridazine) and neuroleptic malignant syndrome (a potentially fatal complication of antipsychotic treatment). Blood dyscrasias such as agranulocytosis, leukopenia and neutropenia are possible with thioridazine treatment.
Thioridazine has the following binding profile:
|Biologic Protein||Binding affinity (Ki[nM])||Binding affinity of Mesoridazine (Ki [nM])||Binding affinity of Sulforidazine (Ki [nM])||Notes|
|5-HT2A||27.67||4.76 (HB)||ND||The ratio of 5-HT2A to D2 receptor binding is believed to dictate whether or not most antipsychotics are atypical or typical. In thioridazine's case its ratio of 5-HT2A to D2 receptor binding is below the level that's believed to be required for atypicality despite its relatively low extrapyramidal side effect liability in practice.|
|5-HT2C||53||157||ND||Believed to play a role in the weight gain-promoting effects of antipsychotics.|
|α1A||3.15||2 (HB)||ND||Likely the receptor responsible for the orthostatic hypotension known to occur in individuals on thioridazine.|
|M1||12.8||10||ND||This receptor is believed to be the chief receptor responsible for the anticholinergic side effects of thioridazine (e.g. dry mouth, constipation, blurred vision, etc.). Likely plays a role in thioridazine's low extrapyramidal side effect liability as anticholinergic drugs such as benzatropine are routinely given to treat extrapyramidal side effects resulting from antipsychotic treatment.|
|D2||0.4||4.3||0.25||Believed to be the receptor responsible for the therapeutic effects of antipsychotics.|
|hERG||191||ND||ND||Likely involved in thioridazine's cardiac effects.|
|H1||16.5||1.81 (HB)||ND||Likely responsible for the sedating effects of thioridazine.|
|H2||136||ND||ND||Regulates the release of hydrochloric acid into the stomach.|
Note: The Binding affinities given are towards cloned human receptors unless otherwise specified
HB - Human brain receptor.
RC - Cloned rat receptor.
ND - No data.
Thioridazine is a racemic compound with two enantiomers, both of which are metabolized, according to Eap et al., by CYP2D6 into (S)- and (R)-thioridazine 2-sulfoxide, better known as mesoridazine, and into (S)- and (R)-thioridazine-5-sulfoxide. Mesoridazine is in turn metabolized into sulforidazine. Thioridazine is an inhibitor of CYP1A2 and CYP3A2.
The manufacturer Novartis/Sandoz/Wander of the brands of thioridazine, Mellaril in the USA and Canada and Melleril in Europe, discontinued the drug worldwide in June 2005.
The usual dosage was 10–75 mg per day for mild cases to 600–800 mg per day for severely disturbed patients.
Thioridazine is still available from other manufacturers as a generic drug with the precaution that it is used only in psychotic patients refractory to other forms of drug treatment. ECG-monitoring and frequent white blood cell counts are required before initiating therapy and in close intervals afterwards. Low-dose thioridazine (10–50 mg per day) is somewhat popular in Russia for the treatment of somatoform disorders, panic attacks, hyperactive-impulsive type of ADHD and insomnia associated with alcohol withdrawal.
A multi-year UK study by the Alzheimer's Research Trust suggested that this and other neuroleptic anti-psychotic drugs commonly given to Alzheimer's patients with mild behavioural problems often make their condition worse. The study concluded that
|“||For most patients with AD, withdrawal of neuroleptics had no overall detrimental effect on functional and cognitive status and by some measures improved functional and cognitive status. Neuroleptics may have some value in the maintenance treatment of more severe neuropsychiatric symptoms, but this possibility must be weighed against the unwanted effects of therapy. The current study helps to inform a clinical management strategy for current practice, but the considerable risks of maintenance therapy highlight the urgency of further work to find, develop, and implement safer and more effective treatment approaches for neuropsychiatric symptoms in people with AD.||”|
|This section requires expansion. (June 2008)|
- Shvartsburd, A; Sajadi, C; Morton, V; Mirabi, M; Gordon, J; Smith, RC (August 1984). "Blood levels of haloperidol and thioridazine during maintenance neuroleptic treatment of schizophrenic outpatients". Journal of Clinical Psychopharmacology 4 (4): 194–198. doi:10.1097/00004714-198408000-00004. PMID 6470190.
- "SHARED CARE PROTOCOL Thioridazine" (PDF). NHS Lothian Joint Formulary. March 2012.
- Robertson A, MacDonald C (July 1984). "Atypical neuroleptics clozapine and thioridazine enhance amphetamine-induced stereotypy". Pharmacol. Biochem. Behav. 21 (1): 97–101. doi:10.1016/0091-3057(84)90137-0. PMID 6540455.
- Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY (March 2002). "Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum". Neuropsychopharmacology 26 (3): 325–39. doi:10.1016/S0893-133X(01)00312-8. PMID 11850147.
- Brunton, L. L.; Chabner, B.; Knollmann, B. C., eds. (2011). Goodman & Gilman's The Pharmacological Basis of Therapeutics (12th ed.). New York: McGraw-Hill. ISBN 978-0-07-162442-8.
- Kirchner, V; Kelly, CA; Harvey, RJ (2001). "Thioridazine for dementia". The Cochrane Database of Systematic Reviews (3): CD000464. doi:10.1002/14651858.CD000464. PMID 11686961.
- Amaral L, Boeree MJ, Gillespie SH, Udwadia ZF, van Soolingen D (June 2010). "Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!". Int. J. Antimicrob. Agents 35 (6): 524–6. doi:10.1016/j.ijantimicag.2009.12.019. PMID 20188526.
- Amaral, L; Viveiros, M (May 2012). "Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections". International Journal of Antimicrobial Agents 39 (5): 376–380. doi:10.1016/j.ijantimicag.2012.01.012. PMID 22445204.
- Thanacoody, HKR (November 2007). "Thioridazine: resurrection as an antimicrobial agent?". British Journal of Clinical Pharmacology 64 (5): 566–574. doi:10.1111/j.1365-2125.2007.03021.x. PMC 2203271. PMID 17764469.
- Thorsing, M; Klitgaard, JK; Atilano, ML; Skov, MN; Kolmos, HJ; Filipe, SR; Kallipolitis, BH (May 2013). "Thioridazine Induces Major Changes in Global Gene Expression and Cell Wall Composition in Methicillin-Resistant Staphylococcus aureus USA300". PLoS One 8 (5): e64518. doi:10.1371/journal.pone.0064518. PMID 23691239.
- Purhonen, M; Koponen, H; Tiihonen, J; Tanskanen, A (November 2012). "Outcome of patients after market withdrawal of thioridazine: A retrospective analysis in a nationwide cohort". Pharmacoepidemiology and Drug Safety 21 (11): 1227–1231. doi:10.1002/pds.3346. PMID 22941581.
- "WHO Pharmaceuticals Newsletter 2005, No. 04: REGULATORY MATTERS: Thioridazine - Sale discontinued in Canada". Essential Medicines and Health Products Information Portal 4 (2) (World Health Organization). 2005. p. 5. Retrieved 28 October 2013.
- "Withdrawal of thioridazine". Australian Prescriber 30 (3): 82. June 2007.
- "THIORIDAZINE HYDROCHLORIDE tablet, film coated [Mutual Pharmaceutical]". DailyMed. Mutual Pharmaceutical. September 2010. Retrieved 28 October 2013.
- Fenton, M; Rathbone, J; Reilly, J; Sultana, A (July 2007). "Thioridazine for schizophrenia". The Cochrane Database of Systematic Reviews (3): CD001944. doi:10.1002/14651858.CD001944.pub2. PMID 17636691.
- Keks, N; McGrath, J; Lambert, T; Catts, S; Vaddadi, K; Burrows, G; Varghese, F; George, T; Hustig, H; Burnett, P; et al. (November 1994). "The Australian multicentre double-blind comparative study of remoxipride and thioridazine in schizophrenia". Acta Psychiatrica Scandinavica 90 (5): 358–365. doi:10.1111/j.1600-0447.1994.tb01607.x. PMID 7872041.
- Fornaro, P; Calabria, G; Corallo, G; Picotti, GB (July 2002). "Pathogenesis of degenerative retinopathies induced by thioridazine and other antipsychotics: a dopamine hypothesis". Documenta Ophthalmologica 105 (1): 41–49. doi:10.1023/A:1015768114192. PMID 12152801.
- "Martindale: The Complete Drug Reference". Medicines Complete. The Pharmaceutical Press. 18 August 2010. Retrieved 28 October 2013.
- "Selected adverse effects of antipsychotic medications for schizophrenia". UpToDate. Wolters Kluwer Health. Retrieved 24 October 2013.
- Roth, BL; Driscol, J (12 January 2011). "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 28 October 2013.
- PubChem Substance Summary: Mesoridazine National Center for Biotechnology Information.
- Eap CB, Guentert TW, Schaublin-Loidl M, Stabl M, Koeb L, Powell K, Baumann P (Mar 1996). "Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin". Clinical Pharmacology & Therapy 59 (3): 322–31. doi:10.1016/S0009-9236(96)80010-5. PMID 8653995.
- PubChem Substance Summary: Sulforidazine National Center for Biotechnology Information.
- Daniel WA, Syrek M, Ryłko Z, Kot M (2001). "Effects of phenothiazine neuroleptics on the rate of caffeine demethylation and hydroxylation in the rat liver". Pol J Pharmacol 53 (6): 615–21. PMID 11985335.
- "Medication 'worsens Alzheimer's'". BBC News. 1 April 2008. Retrieved 2008-04-01.
Neuroleptics provided no benefit for patients with mild behavioural problems, but were associated with a marked deterioration in verbal skills.
- Ballard C, Lana MM, Theodoulou M, Douglas S, McShane R et al. (2008). Brayne, Carol, ed. "A Randomised, Blinded, Placebo-Controlled Trial in Dementia Patients Continuing or Stopping Neuroleptics (The DART-AD Trial)". PLOS Medicine 5 (4, e76): e76. doi:10.1371/journal.pmed.0050076. PMC 2276521. PMID 18384230.
- Bourquin, J. -P.; Schwarb, G.; Gamboni, G.; Fischer, R.; Ruesch, L.; Guldimann, S.; Theus, V.; Schenker, E.; Renz, J. (1958). "Synthesen auf dem Phenothiazin-Gebiet. 2. Mitteilung. N-substituierte Mercaptophenothiazin-Derivate". Helvetica Chimica Acta 41 (4): 1072. doi:10.1002/hlca.19580410420.
- Norton, T. R. (1946). "The Synthesis of Some Substituted 8-Aminoquinolines 1". Journal of the American Chemical Society 68 (8): 1572–1576. doi:10.1021/ja01212a058.
- PubChem Substance Summary: Thioridazine National Center for Biotechnology Information,.
- Antipsychotic Mellaril Removed from Market Schizophrenia Daily News Blog.
- U.S. National Library of Medicine: Drug Information Portal - Thioridazine